Bright Minds Biosciences Inc. (DRUG)
NASDAQ: DRUG · Real-Time Price · USD
90.01
-5.98 (-6.23%)
At close: Jan 8, 2026, 4:00 PM EST
90.00
-0.01 (-0.01%)
After-hours: Jan 8, 2026, 7:45 PM EST
Bright Minds Biosciences Employees
Bright Minds Biosciences had 26 employees as of September 30, 2025. The number of employees increased by 25 or 2,500.00% compared to the previous year.
Employees
26
Change (1Y)
25
Growth (1Y)
2,500.00%
Revenue / Employee
n/a
Profits / Employee
-$337,686
Market Cap
672.50M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 26 | 25 | 2,500.00% |
| Sep 30, 2024 | 1 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
DRUG News
- 1 day ago - Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock - GlobeNewsWire
- 1 day ago - Bright Minds Biosciences: Positive BREAKTHROUGH Study Data Warrants 'Strong Buy' Rating - Seeking Alpha
- 2 days ago - Bright Minds Biosciences Announces Launch of US$100 Million Public Offering - GlobeNewsWire
- 2 days ago - New Bright Minds Epilepsy Drug Cuts Seizures, Lifts Stock On Tuesday - Benzinga
- 2 days ago - Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE) - GlobeNewsWire
- 3 days ago - Bright Minds to Announce Topline Results for BMB-101 Phase 2 Trial in Absence Seizures and Developmental and Epileptic Encephalopathies on Tuesday, January 6, 2026 - GlobeNewsWire
- 6 weeks ago - Bright Minds Biosciences to Present at Piper Sandler 37th Annual Healthcare Conference and 2025 AES Annual Meeting - GlobeNewsWire
- 7 weeks ago - Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Experts in Prader-Willi Syndrome (PWS) - GlobeNewsWire